Title
Category
Credits
Event date
Cost
A New Wave of Topical Therapies for Atopic Dermatitis: Comparing Treatment Approaches
  • LivDerm
  • TME
  • 1.00 AANP
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Topical therapies are considered the mainstay treatment for atopic dermatitis (AD). However, traditional topicals such as corticosteroids and calcineurin inhibitors are associated with limitations for use and safety concerns. In addition, treatment guidelines for AD provide few to no recommendations for selecting therapies and, as a result, treatment selection for each patient can be complex and subjective. New targeted topical therapies are becoming increasingly available, and clinicians must be familiar with the latest clinical data and how to utilize them in clinical practice.
PAINWeek 2024 Digital All Access
  • PAINWeek
  • 80.00 AANP
  • 80.00 ACCME (All Other)
  • 80.00 ACCME (MD/DO Only)
  • 80.00 ACPE Pharmacy
  • 80.00 ANCC
  • 80.00 APA
$899.00
PAINWeek remains the US pain conference with the most expansive curriculum providing practical knowledge and tools for healthcare professionals managing acute and chronic pain. Attendees will be able to engage in education that fosters safe, effective, and equitable pain management and treatment practices in clinical practice by providing evidence-based and rigorously tested clinical medical education from expert, experienced, and adequately credentialed medical professionals.
Addressing Unmet Needs and Disease Burden in Chronic Spontaneous Urticaria: A Clinical Escape Room Challenge
  • LivDerm
  • TME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 Participation
$0.00
Chronic spontaneous urticaria (CSU) has unpredictable symptoms without an obvious external cause; however, the symptoms of CSU, such as hives, itching and swelling, mimic an allergic reaction, and there is often significant time spent finding an external trigger. Despite current treatment options for CSU, treatment resistance and poor symptom control remain significant challenges; only 40% of patients achieve complete symptom control with standard therapy.